Examples include mutations in RNF43 (Steinhart et al., 2017) or PMS2 (Khagi et al., 2017), which could mark clonal subtypes that may make the tumor responsive to specific agents, such as checkpoint inhibitors. This evidence concerns the gene RNF43 and neoplasm.